[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ferroptosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ferroptosis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100648553","the-effect-of-cardiac-rehabilitation-on-ferroptosis-in-patients-with-coronary-artery-disease-100648553",false,"NCT07722637","The Effect of Cardiac Rehabilitation on Ferroptosis in Patients With Coronary Artery Disease","Evaluation of Ferroptosis-Related Biomarkers in Individuals With Coronary Artery Disease: The Impact of Cardiac Rehabilitation","Inclusion Criteria:\n\nPatients With Coronary Artery Disease (CAD):\n\n* Age between 18 and 75 years.\n* Diagnosis of coronary artery disease within the previous 3 months.\n* Eligible to participate in a cardiac rehabilitation program or voluntarily decline participation in the cardiac rehabilitation program.\n* Peak exercise capacity of ≥5 metabolic equivalents (METs).\n* Able to undergo cardiopulmonary exercise testing (CPET).\n* Able to understand the study procedures and provide written informed consent.\n\nHealthy Controls:\n\n* Age between 18 and 75 years.\n* No history of coronary artery disease or other cardiovascular diseases.\n* No history of chronic systemic diseases, including diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, inflammatory or autoimmune diseases, or malignancy.\n* Not receiving regular medication.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\nPatients With Coronary Artery Disease (CAD):\n\n* Decompensated heart failure.\n* Unstable angina pectoris.\n* Uncontrolled or complex ventricular arrhythmias.\n* Severe pulmonary hypertension.\n* Neurological, orthopedic, or musculoskeletal disorders limiting exercise performance.\n* Absolute contraindications to cardiopulmonary exercise testing or cardiac rehabilitation according to current clinical guidelines.\n* Chronic kidney failure or chronic liver disease.\n* Active infection.\n* Active inflammatory or autoimmune disease.\n* Active malignancy or history of malignancy.\n* Pregnancy.\n* Cognitive or psychiatric disorders that would interfere with study participation or protocol compliance.\n\nHealthy Controls:\n\n* History of coronary artery disease or other cardiovascular diseases.\n* History of chronic systemic diseases, including diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, inflammatory or autoimmune diseases, or malignancy.\n* Regular medication use within the previous 6 months.\n* Active infection.\n* Pregnancy.\n* Age younger than 18 years or older than 75 years.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","Coronary artery disease (CAD) remains a major global health concern and is the leading cause of cardiovascular mortality worldwide. Cardiac rehabilitation (CR) is a comprehensive, evidence-based intervention that integrates exercise training with optimal medical management and has been shown to improve clinical outcomes in patients with CAD. The primary objective of this study is to investigate the effects of cardiac rehabilitation on ferroptosis, an iron-dependent form of regulated cell death, in patients with coronary artery disease.\n\nA total of 90 participants will be enrolled in the study after providing written informed consent. The study population will consist of three groups: 30 patients with CAD who participate in a cardiac rehabilitation program, 30 patients with CAD who voluntarily decline participation in cardiac rehabilitation, and 30 age- and sex-matched healthy volunteers without any known chronic disease. Peripheral venous blood samples will be collected from patients undergoing cardiac rehabilitation both before the initiation of the rehabilitation program and upon its completion. A single blood sample will be obtained from patients who decline participation in cardiac rehabilitation and from healthy control participants.\n\nTo evaluate ferroptosis-related molecular alterations, the expression levels of the ferroptosis-associated genes GPX4, SLC7A11, ACSL4, FSP1, NRF2, TFRC, and NCOA4 will be analyzed. In addition, serum concentrations of ferroptosis-related biomarkers, including free iron, 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), and GPX4 protein, will be measured. The molecular and biochemical parameters will be compared among the three study groups, and changes in ferroptosis-related biomarkers before and after the cardiac rehabilitation program will be evaluated in patients undergoing cardiac rehabilitation.",[28,29,30],"Coronary Artery Disease (CAD)","Cardiac Rehab","Ferroptosis",[32,33,34],"cardiac rehabilitation","ferroptosis","Coronary artery disease","RECRUITING","2026-07-28",{"date":38,"type":39},"2026-07-29","ACTUAL",{"date":41,"type":39},"2026-01-01",{"date":43,"type":22},"2026-11-15",{"name":45,"class":46},"TC Erciyes University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100510256","ferroptosis-study-in-sf3b1-mutant-myelodysplastic-syndromes-fermds-100510256","NCT05924074","Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)","FerMDS","Inclusion Criteria:\n\nFor all :\n\n* Patients of legal age (age ≥ 18 years)\n* Subjects affiliated to or benefiting from a social security scheme\n* Free, written and informed consent signed by the participant and the investigator\n\nFor MDS patients :\n\n* Sampling at diagnosis for MDS patients (WHO 2016 criteria)\n* Presence of ring sideroblasts on bone marrow smear\n\nFor MGUS patients :\n\n\\- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).\n\nExclusion Criteria:\n\nFor all\n\n* Patient transfused with red blood cells within 120 days prior to collection\n* Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection\n* Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda\n* Person under a legal protection measure (legal protection, guardianship or curatorship)\n* Person deprived of liberty by judicial or administrative decision\n* Person who is unable to give consent\n* Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol",{"count":56,"type":22},80,[25],"Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.",[60,30],"Myelodysplastic Syndromes","2025-03-18",{"date":63,"type":39},"2025-03-19",{"date":65,"type":39},"2025-02-21",{"date":67,"type":22},"2027-02",{"name":69,"class":46},"University Hospital, Bordeaux",3]